Home -> Law Blog Directory -> Patent Law Blogs -> Patent Docs

Patent Law

: Patent Docs

Patent Profile: OncoGenex Announces Issuance of Patent for Antisense Cancer Therapeutic

By Donald Zuhn, Kevin Noonan, Chris Singer, Sherri Oslick, and Jason Derry

By Donald Zuhn -- Last month, OncoGenex Pharmaceuticals, Inc. announced that the U.S. Patent and Trademark Office had issued U.S. Patent No. 7,569,551. The '551 patent is directed to a method of enhancing cancer cell chemo- or radiation-sensitivity using an antisense oligodeoxynucleotide targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene. The inventors found that that administration of TRPM-2 antisense oligodeoxynucleotides can reduce the expression of TRPM-2, and as a result enhance the sensitivity of cancer cells to chemotherapeutic agents or radiotherapy either in vitro and in vivo. While the '551 patent is assigned to the University of British Columbia, Oncogenex...

Full post as published by Patent Docs on September 09, 2009 (boomark / email).